Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
It is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety
of Daratumumab in combination with Bortezomib and Dexamethasone in patients about 28 patients
with Relapsed or Refractory Plasmablastic lymphoma.